pozelimab
Trade name: Veopoz
mAbapprovedOrphan Drug FDAFast Track FDA
Approved
Aug 18, 2023
Clinical trial activity
21 trials · 3 clinical orgs · 1 marketing orgs
Phase 1
6
Phase 2
10
Phase 3
8
Phase 4
1
Earliest trial started Jun 1, 2017 (NCT03115996)
Timeline
2010s
Indications
Approved for
Mechanism of action
- Complement C5INHIBITOR
Complement C5 inhibitor
Approval history
- approvedPriority reviewFast trackAug 18, 2023
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
- Multi-specific
- No
Oral
No
Parenteral
Yes
Topical
No
Black box warningFirst in class
Sources
- ChEMBLCHEMBL4298086 ↗
Also known as
- regn3918
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07142343 | Phase 4 | Dec 23, 2025 | Regeneron |
| NCT07154745 | Phase 3 | Dec 19, 2025 | Regeneron |
| NCT07230834 | Phase 1 | Dec 15, 2025 | Regeneron |
| NCT06541704 | Phase 3 | Oct 28, 2024 | Regeneron |
| NCT06479863 | Early Phase 1 (Phase 1) | Aug 8, 2024 | Austin Neuromuscular Center, Regeneron |
| NCT05744921 | Phase 3 | Mar 7, 2023 | Regeneron |
| NCT05133531 | Phase 3 | Jul 31, 2022 | Regeneron |
| NCT05131204 | Phase 3 | Mar 31, 2022 | Regeneron |
| NCT05070858 | Phase 3 | Sep 30, 2021 | Regeneron |
| NCT04940364 | Phase 1 | Aug 4, 2021 | Regeneron |
| NCT04811716 | Phase 2 | Jul 28, 2021 | Regeneron |
| NCT04888507 | Phase 2 | Jul 8, 2021 | Regeneron |
| NCT04601844 | Phase 1 | Nov 16, 2020 | Alnylam Pharmaceuticals, Regeneron |
| NCT04491838 | Phase 1 | Aug 3, 2020 | Regeneron |
| NCT04209634 | Phase 2/Phase 3 (Phase 3) | Dec 30, 2019 | Regeneron |
| NCT04162470 | Phase 3 | Dec 3, 2019 | Regeneron |
| NCT03946748 | Phase 2 | May 16, 2019 | Regeneron |
| NCT03115996 | Phase 1 | Jun 1, 2017 | Regeneron |
| NCT06028594 | N/A | — | Regeneron |
| NCT06003881 | N/A | — | Regeneron |
Showing 20 of 21 trials
Page 1 / 2
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Regeneron | For profit | 21 | 20 | 5 | 2017 |
| Alnylam Pharmaceuticals | For profit | 1 | 0 | 1 | 2020 |
| Austin Neuromuscular Center | Academic/Hospital | 1 | 1 | 1 | 2024 |
3 organizations
Page 1 / 1